Clinical trials recruiting for Leptomeningeal Metastasis

Phase breakdown

Drugs and treatments being studied

Self-screener

Recruiting trials

• A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
  NCT06901817 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
  NCT05257967 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
  NCT05800275 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  NCT07398599 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
  NCT06399926 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
  NCT06643000 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
  NCT06304441 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
  NCT06230055 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
  NCT06663306 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
  NCT06296745 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
  NCT07348965 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
  NCT06431685 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Leptomeningeal Metastasis often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Leptomeningeal Metastasis trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.